Quantum Devices, Inc. teams with NASA and launches clinical trial to provide drug-free relief to cancer patients suffering the ravages of oral mucositis.

Barneveld, WI November 8, 2005: Quantum Devices, Inc. has received a NASA Phase III contract to launch their HEALS® Lighting technology into a Phase III Clinical Trial proving safety and efficacy for cancer patients suffering the ravages of oral mucositis.

Oral mucositis affects the majority of cancer patients receiving aggressive chemotherapy and radiation therapy. Morbidity associated with chemotherapy induced oral mucositis can be a significant problem in the treatment of the cancer patient. Mucositis may increase the risk of local and systemic infection, limit or prevent oral intake of food or medication, interfere with speech, and cause significant pain. The most distressing complication of cancer therapy reported by patients is oral mucositis.

Earlier NASA sponsored research has indicated a once a day, 90 second application of the HEALS lighting technology significantly reduces the pain and open ulcers of mucositis. When the HEALS treatment is initiated before chemotherapy and radiation therapy, the presentation of mucositis is significantly reduced.

Dr. Harry Whelan, of the Medical College of Wisconsin, will have the Primary Investigator responsibility. The primary site for the trial will be the Medical College of Wisconsin and their associated teaching hospitals, Froedtert Memorial Lutheran Hospital and Children’s Hospital of Wisconsin. The University of Alabama – Birmingham and their associated teaching hospitals will collaborate in the study.

For Release 3:30 p.m. November 8, 2005